Solid-Supported Sulfonylhydroxylamine as an Effective N-Aminating Agent of Anilines

Abstract

An effective method for the synthesis of aryl hydrazines by amination of anilines using the solid-supported phenylsulfonylhydroxylamine was described. Treatment of aniline with the solid-supported aminating agent, followed by removal of the resin, provided the corresponding hydrazine in 21% yield. The resulting hydrazines were directly adapted to the solid-phase synthesis of indoles, providing nine naltrindole derivatives varying the substituents on the aromatic rings.

Key words

electrophilic aminations - hydrazines - indoles - naltrindoles - solid-phase synthesis

References

• For reviews on synthesis of heterocycles, see:
• 1a Krchnak V. Holladay MW. Chem. Rev.  2002,  102:  61 
• 1b Franzen RG. J. Comb. Chem.  2000,  2:  195 
• 1c Horton DA. Bourne GT. Smythe ML. Chem. Rev.  2003,  103:  893 
• For recent studies on synthesis of aryl hydrazines and their derivatives, see:
• 2a Wang Z. Skerlj RT. Bridger GJ. Tetrahedron Lett.  1999,  40:  3543 
• 2b Wagaw S. Yang HB. Buchwald SL. J. Am. Chem. Soc.  1998,  120:  6621 
• 2c Hartwig JF. Angew. Chem. Int. Ed.  1998,  37:  2090 
• 2d Demers JP. Klaubert DH. Tetrahedron Lett.  1987,  28:  4933 
• 3 On the biological activity of indoles, see: Sunberg RJ. Indoles   Academic Press; London: 1996. and references therein
• 4 Haddad N. Baron J. Tetrahedron Lett.  2002,  43:  2171 ; and references therein
• 5 Hunsberger IM. Shaw ER. Fugger J. Ketcham R. Lednicer D. J. Org. Chem.  1956,  21:  394 
• 6 Brown DW. Mahon MF. Ninan A. Sainsbury M. Shertzer HG. Tetrahedron  1993,  49:  8919 
• 7 For a review on sulfonylhydroxylamine, see: Tamura Y. Minamikawa J. Ikeda M. Synthesis  1977,  1 
• For synthesis of sulfonylhydroxylamine, see:
• 8a Glover EE. Rowbottom KT. J. Chem. Soc., Perkin Trans. 1  1976,  367 
• 8b Batori S. Timari G. Koczka I. Hermecz I. Bioorg. Med. Chem. Lett.  1996,  6:  1507 
• 8c Greck C. Bischoff L. Girard A. Hajicek J. Genet JP. Bull. Soc. Chim. Fr.  1994,  131:  429 
• 9 Explosion in attempting to dry O-mesitylenesulfonyl-hydroxylamine has been reported, see: Scopes DIC. Kluge AF. Edwards JA. J. Org. Chem.  1977,  42:  376 
• For solid-supported reagent, see:
• 10a Booth RJ. Hodges JC. Acc. Chem. Res.  1999,  32:  18 
• 10b Parlow JJ. Devraj RV. South MS. Curr. Opin. Chem. Biol.  1999,  3:  320 
• 10c Thompson LA. Curr. Opin. Chem. Biol.  2000,  4:  324 
• 10d Ley SV. Baxendale IR. Bream RN. Jackson PS. Leach AG. Longbottom DA. Nesi M. Scott JS. Storer RI. Taylor SJ. J. Chem. Soc., Perkin Trans. 1  2000,  3815 
• 10e Guillier F. Orain D. Bradley M. Chem. Rev.  2000,  100:  2091 
• 11a Portoghese PS. Sultana M. Nagase H. Takemori AE. J. Med. Chem.  1988,  31:  281 
• 11b Portoghese PS. Sultana M. Takemori AE. J. Med. Chem.  1990,  33:  1714 
• 15 Robinson R. The Fischer Indole Synthesis   Wiley-Interscience; New York: 1982. 
• 16a Tanaka H. Ohno H. Kawamura K. Ohtake A. Nagase H. Takahashi T. Org. Lett.  2003,  5:  1159 
• 16b Ohno H. Tanaka H. Takahashi T. Synlett  2004,  508 

12

Procedure for the Preparation of 7.
To a mixture of PS-TsCl (Argonout, 1.97 mmol/g, 2.0 g, 3.9 mmol) and N-Boc-hydroxylamine (1.05 g, 7.9 mmol) in THF (32 mL) was added THF solution (4 mL) of Et₃N (1.1 mL, 7.9 mmol) slowly at 0 °C. The mixture was shaken for 1.5 h at r.t. After filtration of the mixture, the resulting resin was washed with THF, H₂O, and THF, and dried in vacuo to give resin-supported N-Boc sulfonyl hydroxylamine 7 (2.6 g). IR (resin): 1475, 1396, 1173 cm^-1. Anal. Found: C, 68.78; H, 7.40; N, 2.22; Cl, 0.02; S, 5.52%.

13

The ratio was estimated by ¹H NMR measurement of the crude mixture.

14

Typical Experimental Procedure.
To resin-supported N-Boc sulfonyl hydroxylamine (7, 100 mg), TFA (1 mL, pre-cooled at 0 °C) was added at r.t., and the mixture was shaken for 1 min at r.t. After filtration of the mixture, the resulting resin was washed with H₂O, THF, and CH₂Cl₂ (pre-cooled at 0 °C) to give the polystyrene-supported sulfonyl hydroxylamine 1B. The resulting resin was used for next amination without drying. To the resulting resin 1B was added aniline (27 µL, 0.29 mmol) in CH₂Cl₂ (0.5 mL, pre-cooled at 0 °C), and the mixture was shaken for 10 min at r.t. After filtration of the mixture followed by washing with CH₂Cl₂, the resulting resin were treated with CH₂Cl₂-HCl (10 M) in MeOH (1:1), filtered, and then washed with CH₂Cl₂-HCl (10 M) in MeOH (1:1). The combined filtrates were evaporated, and dried in vacuo to give of crude phenylhydrazine HCl (17.1 mg). Further purification was achieved by silica gel column chromatography followed by adding 10 M HCl in MeOH to give phenylhydrazine HCl (4.0 mg, 28 µmol).

17

The lower yield than previously reported [16a] was due to the different ways of estimation of the yield. The yield was determined by measurement of mass weight of cleavage product in the former paper, on the other hand in this paper the yield is isolated yield.

18

Spectra of 8d: ¹H NMR (400 MHz, CD₃OD): δ = 0.13-0.23 (2 H, m), 0.52-0.61 (2 H, m), 0.93 (1 H, m), 1.30 (3 H, t, J = 7.6 Hz), 1.72 (1 H, d, J = 12.2 Hz), 2.28-2.50 (4 H, m), 2.56 (1 H, d, J = 15.9 Hz), 2.73 (1 H, d, J = 15.9 Hz), 2.73-2.90 (4 H, m), 3.17 (1 H, d, J = 18.6 Hz), 3.40 (1 H, d, J = 6.3 Hz), 5.59 (1 H, s), 6.53 (1 H, d, J = 8.1 Hz), 6.56 (1 H, d, J = 8.1 Hz), 7.00 (1 H, d, J = 1.7 Hz), 7.34 (1 H, d, J = 1.7 Hz). ¹³C NMR (150.8 MHz, CD₃OD): δ = 4.2, 4.8, 10.3, 14.6, 24.1, 25.1, 29.8, 32.8, 45.0, 60.4, 63.4, 74.4, 85.7, 111.1, 113.0, 118.2, 119.6, 119.7, 124.4, 126.0, 129.3, 130.2, 131.8, 131.9, 135.8, 140.8, 144.5. MS (ESI): 521 [M + H]⁺.
Spectra of 8e: ¹H NMR (400 MHz, CD₃OD): δ = 0.13-0.22 (2 H, m), 0.51-0.60 (2 H, m), 0.93 (1 H, m), 1.73 (1 H, d, J = 12.5 Hz), 2.28-2.47 (4 H, m), 2.49 (3 H, s), 2.57 (1 H, d, J = 15.9 Hz), 2.68-2.85 (2 H, m), 2.76 (1 H, d, J = 15.9 Hz), 3.17 (1 H, d, J = 18.6 Hz), 3.40 (1 H, d, J = 6.3 Hz), 5.59 (1 H, s), 6.52 (1 H, d, J = 8.1 Hz), 6.55 (1 H, d, J = 8.1 Hz), 6.90 (1 H, d, J = 8.4 Hz), 7.16 (1 H, d, J = 8.4 Hz). ¹³C NMR (150.8 MHz, CD₃OD): δ = 4.2, 4.8, 10.3, 14.1, 24.1, 29.8, 32.7, 45.0, 60.4, 63.5, 74.4, 85.8, 111.8, 117.8, 118.2, 119.3, 119.6, 120.9, 125.9, 126.2, 128.4, 131.5, 131.9, 138.5, 140.8, 144.5. MS (ESI): 463 [M + H]⁺.
Spectra of 8f: ¹H NMR (400 MHz, CD₃OD): δ = 0.15-0.24 (2 H, m), 0.52-0.62 (2 H, m), 0.95 (1 H, m), 1.26-1.42 (18 H, m), 1.74 (1 H, m), 2.35-2.49 (4 H, m), 2.71-2.81 (3 H, m), 3.18-3.26 (2 H, m), 3.36 (1 H, d, J = 6.3 Hz), 5.61 (1 H, s), 6.53 (1 H, d, J = 8.2 Hz), 6.56 (1 H, d, J = 8.2 Hz), 7.05 (1 H, d, J = 1.7 Hz), 7.20 (1 H, d, J = 1.7 Hz). ¹³C NMR (150.8 MHz, CD₃OD): δ = 4.3, 4.7, 10.3, 24.2, 31.9, 32.2, 33.0, 35.6, 36.3, 36.5, 44.9, 48.0, 60.5, 63.9, 75.0, 86.6, 107.0, 108.9, 115.2, 118.2, 119.5, 122.6, 125.9, 130.9, 132.1, 140.1, 140.8, 144.3, 144.8, 145.1. MS (ESI): 527 [M + H]⁺.
Spectra of 8g: ¹H NMR (400 MHz, CD₃OD): δ = 0.15-0.24 (2 H, m), 0.52-0.61 (2 H, m), 0.94 (1 H, m), 1.73 (1 H, m), 1.81-1.91 (4 H, m), 2.31-2.49 (4 H, m), 2.59 (1 H, d, J = 15.9 Hz), 2.75-2.87 (7 H, m), 3.17 (1 H, d, J = 18.6 Hz), 3.41 (1 H, d, J = 5.9 Hz), 5.60 (1 H, s), 6.52 (1 H, d, J = 8.2 Hz), 6.54 (1 H, d, J = 8.2 Hz), 6.67 (1 H, d, J = 8.1 Hz), 7.10 (1 H, d, J = 8.1 Hz). ¹³C NMR (150.8 MHz, CD₃OD): δ = 4.2, 4.8, 10.2, 24.2, 24.2, 24.9, 25.4, 30.0, 30.6, 32.7, 45.0, 49.9, 60.4, 63.5, 74.4, 86.3, 116.7, 118.1, 119.4, 120.4, 121.5, 125.3, 125.9, 129.5, 131.3, 132.1, 137.7, 140.8, 144.5, 150.4. MS (ESI): 469 [M + H]⁺.
Spectra of 8h: ¹H NMR (400 MHz, CD₃OD): δ = 0.12-0.22 (2 H, m), 0.49-0.60 (2 H, m), 0.92 (1 H, m), 1.75 (1 H, d, J = 12.7 Hz), 2.27-2.46 (4 H, m), 2.66 (1 H, d, J = 15.6 Hz), 2.71-2.76 (1 H, m), 2.83 (1 H, d, J = 18.6 Hz), 2.84 (1 H, d, J = 15.9 Hz), 3.17 (1 H, d, J = 18.6 Hz), 3.42 (1 H, d, J = 6.3 Hz), 5.68 (1 H, s), 6.54 (1 H, d, J = 8.2 Hz), 6.57 (1 H, d, J = 8.2 Hz), 7.45-7.49 (1 H, m), 7.51-7.55 (1 H, m), 7.58 (1 H, s), 8.19-8.23 (2 H, m). ¹³C NMR (150.8 MHz, CD₃OD): δ = 4.2, 4.7, 10.2, 24.1, 29.7, 32.7, 44.8, 60.3, 63.3, 74.4, 85.7, 112.6, 118.0, 119.5, 119.7, 121.7, 122.8, 123.5, 123.9, 125.3, 125.8, 125.9, 126.8, 128.2, 129.9, 131.7, 132.3, 140.6, 144.4. MS (ESI): 499 [M + H]⁺.
Spectra of 8i: ¹H NMR (400 MHz, CD₃OD): δ = 0.12-0.24 (2 H, m), 0.51-0.62 (2 H, m), 0.87-0.97 (1 H, m), 1.73-1.76 (1 H, m), 2.28-2.50 (4 H, m), 2.63 (1 H, d, J = 14.6 Hz), 2.72-2.88 (2 H, m), 2.81 (1 H, d, J = 15.6 Hz), 3.18 (1 H, d, J = 18.6 Hz), 3.42 (1 H, d, J = 6.6 Hz), 3.81 (1 H, d, J = 22.0 Hz), 3.90 (1 H, d, J = 21.7 Hz), 5.63 (1 H, s), 6.54 (1 H, d, J = 8.1 Hz), 6.56 (1 H, d, J = 8.1 Hz), 7.15-7.19 (1 H, m), 7.26-7.30 (1 H, m), 7.31 (1 H, d, J = 8.1 Hz), 7.41 (1 H, d, J = 8.3 Hz), 7.46 (1 H, d, J = 7.3 Hz), 7.68 (1 H, d, J = 7.6 Hz). ¹³C NMR (150.8 MHz, CD₃OD): δ = 4.2, 4.8, 10.3, 24.2, 30.1, 32.7, 35.2, 45.0, 60.4, 63.5, 74.4, 86.1, 112.2, 112.4, 118.2, 118.5, 119.6, 119.8, 125.6, 126.0, 126.1, 126.5, 127.4, 127.6, 131.0, 132.1, 135.5, 137.8, 140.9, 143.5, 144.4, 144.6. MS (ESI): 503 [M + H]⁺.